Effect of membrane permeability on survival of hemodialysis patients

Journal of the American Society of Nephrology

Volumn 20, Issue 3, 2009, Pages 462-464

  Cheung, Alfred K ^a,c   Greene, Tom ^b,c  

^a Medical Service   (United States)

^b Utah USA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; BETA 2 MICROGLOBULIN; LEPTIN; PARATHYROID HORMONE; SERUM ALBUMIN;

ARTIFICIAL KIDNEY; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; EDITORIAL; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOALBUMINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MEMBRANE PERMEABILITY; PRIORITY JOURNAL;

EID: 62149122939     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009010030     Document Type: Editorial

References (13)

1. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991
2. Coyne DW, Dagogo-Jack S, Klein S, Merabet E, Audrain J, Landt M: High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 32: 1031-1035, 1998
3. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P: Apolipoprotein C-lll, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 25: 258-262, 1999
4. Haag-Weber M, Hörl WH: Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Nephrol Dial Transplant 11[Suppl 2]: 98-100, 1996
5. Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49: 267-275, 2007
6. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
7. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 14: 3251- 3263, 2003
8. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group: Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 65: 2380-2389, 2004
9. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R, Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 20: 645-654, 2009
10. Allon M, Ornt DB, Schwab SJ, Rasmussen C, Delmez JA, Greene T, Kusek JW, Martin AA, Minda S, Hemodialysis (HEMO) Study Group: Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Kidney Int 58: 2178-2185, 2000
11. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, Hemodialysis (HEMO) Study Group: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. J Am Soc Nephrol 10: 117-127, 1999
12. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: Design of a prospective randomised multicentre trial. J Nephrol 12: 85-88, 1999
13. Krieter DH, Falkenhain S, Chalabi L, Collins G, Lemke HD, Canaud B: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int 67: 349-356, 2005